In the current session, Amgen Inc. (NASDAQ:AMGN) is trading at $291.80, after a 0.07% drop. Over the past month, the stock fell by 2.04%, and in the past year, by 7.92%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. Amgen P/E Compared to CompetitorsThe P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Guardant Health Inc. (NASDAQ:GH) is one of the best-performing stocks on Thursday. Guardant Health soared to a fresh record high on Thursday, as investors took heart from an impressive earnings performance and a higher growth outlook for the full-year period. During the trading session, Guardant Health Inc. (NASDAQ:GH) jumped to its highest level of $95.88 before paring gains to end the day just up by 27.87 percent at $92.41 apiec ...

Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

Accessibility StatementSkip Navigation Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from t ...

HUTCHMED (China) (NasdaqGS:HCM) Update / Briefing October 31, 2025 08:00 AM ET Speaker0Hello, everyone. Good evening and good morning. Thank you for joining the HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The performance and results of operations of the HUTCHMED group contained within this presentation are historical in nature, and the past performance is no guarantee of future results. As usual, we will have a Q&A session at the end wh ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Manage ...

https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=174682&wire=4 MLTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL- 17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit ...

中新社香港10月31日电 (记者 戴小橦)10月31日，来到10月最后一个交易日，港股市场呈现调整态势， 三大指数同步走弱。而纵观整个10月，港股IPO市场热度持续高企，单月有超过10家公司成功登陆香港 交易及结算所有限公司(简称"港交所")，市场结构性分化特征愈发鲜明。 银河证券发布研究报告指出，医药板块近期已呈现显著结构性修复趋势。当前二级市场行情回暖驱动一 级市场投融资回升，医疗器械招投标数据已有好转，以旧换新积压需求逐步释放。 方正证券发布的研究报告表示，医药行业景气度正步入新一轮上行周期。行业"出海"订单加速释放，且 整体尚处于成长早期，向上动能强劲。报告看好"出海"能力突出的生物品类上游公司，相信创新药"出 海"将迎来机遇。 招商证券发布研报称，美联储降息促使美国与新兴市场利差收窄、美元走弱，从而吸引国际资金流入香 港等新兴市场，港股中长期有望呈现渐进式上涨。与此同时，美联储降息周期亦有望改善创新药领域的 融资环境，推动研发进展。 31日，港股三大指数齐跌，香港恒生指数跌1.43%，恒生科技指数跌2.37%，国企指数跌1.91%。(完) 10月31日，香港恒生指数收市报25906.65点，下跌37 ...

TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky October IBD Videos Get market updates, educational videos, webinars, and stock analysis. 11/01/2025Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points. 11/01/2025Three S&P 500 components, including JPMorgan Chase and Eli Lilly,... INVESTING RESOURCES Take a Trial Today Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only ...

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agree ...